Travere Therapeutics (TVTX) Reports Topline Results from Pha

Travere Therapeutics (TVTX) Reports Topline Results from Phase 3 DUPLEX Study of Sparsentan

Travere Therapeutics (TVTX) Reports Topline Results from Phase 3 DUPLEX Study of Sparsentan
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Naomi Eichenbaum , Deric Dube , Jula Inrig , Nivi Nehra , Travere Therapeutics Inc , Nasdaq , European Medicines Agency , European Union , Exchange Commission On , Corporate Communications , Company Annual Report On Form , Wall Street , Dual Endothelin Angiotensin Receptor Antagonist , New Drug Application , Conditional Marketing Authorization , Efficacy Endpoints , Two Year Exploratory Endpoints , Important Safety , Endothelin Receptor Antagonists , Upper Limit , Fetal Toxicity , Kidney Injury , Angiotensin System , Acid Reducing Agents , Steroidal Anti Inflammatory Agents , Including Selective , Increasing Serum Potassium , Reproductive Potential , Full Prescribing Information , Travere Therapeutics , Private Securities Litigation Reform Act , Annual Report , Exchange Commission ,